Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Muraglitazar"'
Publikováno v:
Current Molecular Pharmacology
Background: Diabetes mellitus and concomitant dyslipidemia, being referred to as ‘diabetic dyslipidemia’, are the foremost detrimental factors documented to play a pivotal role in cardiovascular illness. Diabetic dyslipidemia is associated with i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bde870be3ea36dd7b423aef8f8f2deda
https://doi.org/10.2174/1874467212666190111165015
https://doi.org/10.2174/1874467212666190111165015
Publikováno v:
J Cardiovasc Pharmacol
The most common complications in patients with type-2 diabetes are hyperglycemia and hyperlipidemia that can lead to cardiovascular disease. Alleviation of these complications constitutes the major therapeutic approach for the treatment of diabetes m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46f875fce9e8571bec724dfeb91e0b85
https://pubmed.ncbi.nlm.nih.gov/33165133
https://pubmed.ncbi.nlm.nih.gov/33165133
Publikováno v:
Journal of Cardiovascular Pharmacology
Gemcabene, a late-stage clinical candidate, has shown efficacy for LDL-C, non-HDL cholesterol, apoB, triglycerides, and hsCRP reduction, all risk factors for cardiovascular disease. In rodents, gemcabene showed changes in targets, including apoC-III,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6bcfaa4f74b129c7d45c0a29a28b24a
https://doi.org/10.1097/fjc.0000000000000580
https://doi.org/10.1097/fjc.0000000000000580
Autor:
Taina Isotalo, Velipekka Suominen, Andres Kotsar, Ilkka Uurto, Teuvo L.J. Tammela, Mari Hämäläinen, Juha-Pekka Salenius, Marita Laurila, Minna Kellomäki
Publikováno v:
Journal of Vascular and Interventional Radiology. 26:124-130
Purpose To evaluate the biocompatibility of a new muraglitazar-eluting polylactide copolymer stent and investigate its ability to prevent the formation of intimal hyperplasia. Materials and Methods Ten self-expandable muraglitazar-eluting poly-96l/4d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6fa3d714da910372c37120bb848ce49a
https://doi.org/10.1016/j.jvir.2014.10.005
https://doi.org/10.1016/j.jvir.2014.10.005
Publikováno v:
The British journal of general practice : the journal of the Royal College of General Practitioners. 67(655)
To answer the questions that arise in relation to a patient’s clinical situation, medical decisions need to be made according to the principles of evidence-based medicine. At this time, the benefits and risks of glycaemic control in patients with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::83a905eb142f22fccc76c5db6e08cd11
https://pubmed.ncbi.nlm.nih.gov/28360054
https://pubmed.ncbi.nlm.nih.gov/28360054
Autor:
Farn-Hsuan Tseng, Chin-Hsiao Tseng
Publikováno v:
Journal of Environmental Science and Health, Part C. 30:368-402
This article reviews available animal studies on the possible link between the use of peroxisome proliferator-activated receptor (PPAR) agonists and bladder cancer, with further discussion on the possible implications to humans. Carcinogenicity studi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1bf9719b4ae93f14e47844323a7b78bb
https://doi.org/10.1080/10590501.2012.735519
https://doi.org/10.1080/10590501.2012.735519
Autor:
Ingrid M. Pruimboom-Brees, Roy L. Kerlin, Daniel Morton, Yvonne Will, Germaine Boucher, David E. Amacher, Omar L. Francone, John C. Pettersen
Publikováno v:
Toxicologic Pathology. 40:810-818
Peroxisome proliferator-activated receptors (PPARs) represent therapeutic targets for the management of type 2 diabetes mellitus and dyslipidemia. Rodent carcinogenicity studies have revealed a link between γ and dual γ/α PPAR agonist treatment an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::943db11caf458076cec87ce66b86e7e4
https://doi.org/10.1177/0192623312441406
https://doi.org/10.1177/0192623312441406
Publikováno v:
Organic Process Research & Development. 14:238-241
Impurity A, observed during the process research and development of muraglitazar, was isolated via preparative HPLC for structural identification using one-dimensional and two-dimensional NMR techniques. The origin of impurity A was identified as ari
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::89287af240cc7ff0ba1b485e354cc044
https://doi.org/10.1021/op9002104
https://doi.org/10.1021/op9002104
Autor:
Samuel M. Cohen, Karen L. Pennington, Shugo Suzuki, Hideki Wanibuchi, Satoko Kakiuchi-Kiyota, Min Wei, Lora L. Arnold
Publikováno v:
Toxicological Sciences. 113:349-357
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors, which belong to the nuclear receptor superfamily. Some PPARgamma agonists, such as pioglitazone, and dual PPARgamma/PPARalpha agonists, such as muraglitaz
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c86127076179af4c4ef102b54577865
https://doi.org/10.1093/toxsci/kfp256
https://doi.org/10.1093/toxsci/kfp256
Autor:
Chang Yell Shin, Dong-Jo Chang, Mi Kyung Kim, Sung-Hyun Moon, Dong-Hyung Shin, Hyun-Jin Kang, Seung-Mann Paek, Kwang-Ok Lee, Bon-Woong Koo, Fu-Nan Li, Young-Ger Suh, Jae Sang Ryu, Nam-Jung Kim, Joong In Lim, Tuong Vy Thi Le, Jong-Wha Jung, Yu Na Chae, Hyun-Ju Park
Publikováno v:
Journal of Medicinal Chemistry. 51:6318-6333
In an effort to develop dual PPARalpha/gamma activators with improved therapeutic efficacy, a series of diaryl alpha-ethoxy propanoic acid compounds comprising two aryl groups linked by rigid oxime ether or isoxazoline ring were designed and synthesi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::746026c97381a1db22c3fa41ec983d4b
https://doi.org/10.1021/jm8003416
https://doi.org/10.1021/jm8003416